News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the American Urological Association Annual Meeting



5/21/2012 10:29:42 AM

MALVERN, Penn.--(BUSINESS WIRE)-- AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520). Solabegron is a novel beta3-adrenoceptor agonist with high affinity and selectivity that is in late stage clinical development for the treatment of OAB and irritable bowel syndrome (IBS).

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES